JP2025513879A - 免疫チェックポイントエンゲージャーによる免疫細胞の抑制 - Google Patents

免疫チェックポイントエンゲージャーによる免疫細胞の抑制 Download PDF

Info

Publication number
JP2025513879A
JP2025513879A JP2024560636A JP2024560636A JP2025513879A JP 2025513879 A JP2025513879 A JP 2025513879A JP 2024560636 A JP2024560636 A JP 2024560636A JP 2024560636 A JP2024560636 A JP 2024560636A JP 2025513879 A JP2025513879 A JP 2025513879A
Authority
JP
Japan
Prior art keywords
cell
cells
ice
engager
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513879A5 (https=
Inventor
デュース トバイアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2025513879A publication Critical patent/JP2025513879A/ja
Publication of JP2025513879A5 publication Critical patent/JP2025513879A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
JP2024560636A 2022-04-13 2023-04-11 免疫チェックポイントエンゲージャーによる免疫細胞の抑制 Pending JP2025513879A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263330539P 2022-04-13 2022-04-13
US63/330,539 2022-04-13
US202363448081P 2023-02-24 2023-02-24
US63/448,081 2023-02-24
PCT/US2023/018189 WO2023200796A1 (en) 2022-04-13 2023-04-11 Immune cell inhibition by immune checkpoint engagers

Publications (2)

Publication Number Publication Date
JP2025513879A true JP2025513879A (ja) 2025-04-30
JP2025513879A5 JP2025513879A5 (https=) 2026-04-15

Family

ID=88330149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560636A Pending JP2025513879A (ja) 2022-04-13 2023-04-11 免疫チェックポイントエンゲージャーによる免疫細胞の抑制

Country Status (7)

Country Link
US (1) US20250268949A1 (https=)
EP (1) EP4507727A4 (https=)
JP (1) JP2025513879A (https=)
CN (1) CN119183385A (https=)
AU (1) AU2023251864A1 (https=)
CA (1) CA3247422A1 (https=)
WO (1) WO2023200796A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024177982A2 (en) * 2023-02-24 2024-08-29 The Regents Of The University Of California Lilrb1 engager cells
WO2025098508A1 (zh) * 2023-11-10 2025-05-15 贝达药业股份有限公司 标记性多肽、治疗剂及其应用
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
CN120340611B (zh) * 2025-04-02 2025-09-23 中瑞德泰生物科技集团有限公司 Car-nk细胞数据的特征提取方法及系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488876A1 (en) * 2002-06-13 2003-12-24 Oregon Health & Science University Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets
US20180133327A1 (en) * 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
JP2020506943A (ja) * 2017-02-07 2020-03-05 メモリアル スローン ケタリング キャンサー センター 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
US11840575B2 (en) * 2019-05-07 2023-12-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Engineered immune cells targeting BCMA and their uses thereof

Also Published As

Publication number Publication date
EP4507727A1 (en) 2025-02-19
WO2023200796A1 (en) 2023-10-19
CA3247422A1 (en) 2023-10-19
EP4507727A4 (en) 2026-04-08
AU2023251864A1 (en) 2024-10-03
US20250268949A1 (en) 2025-08-28
CN119183385A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
US20240043803A1 (en) Innate immune cell silencing by sirp-alpha engager
US20250268949A1 (en) Immune cell inhibition by immune checkpoint engagers
CN111247242B (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
JP2022532174A (ja) 修飾多能性細胞
US20220169988A1 (en) Gene-edited natural killer cells
AU2021228708A1 (en) Methods of making chimeric antigen receptor-expressing cells
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
KR20230017780A (ko) 면역저하성 세포의 반복 투여
JP2024521619A (ja) 操作されたｈｌａ－ｅまたはｈｌａ－ｇを含む低免疫原性細胞
JP2024531234A (ja) 同種異系細胞療法のための遺伝子改変された初代細胞
WO2024046394A1 (zh) 增强受体、表达增强受体的免疫细胞及其用途
JP2024526237A (ja) 同種異系養子細胞療法のための保護されたエフェクター細胞及びその使用
US20250032544A1 (en) Sirpalpha switch receptors
WO2024177975A2 (en) Tim3 engager cells
WO2024177978A1 (en) Lilrb3 engager cells
WO2024177982A2 (en) Lilrb1 engager cells
CN117279651A (zh) 通过修饰的Fc受体的移植细胞保护
WO2026072856A2 (en) Comprehensively immune protected cells
WO2025054202A1 (en) Method of screening a sample comprising a transgene with a unique barcode
WO2022212393A1 (en) Transplanted cell protection via modified fc receptors
CN118434844A (zh) 用于减少补体介导的炎症反应的同种异体细胞疗法的基因修饰的细胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260407